Serotonin, β-amyloid, and cognition in Parkinson disease.
Serotonin, β-amyloid, and cognition in Parkinson disease.
复制标题
DOI：
10.1002/ana.25236
复制
发表时间：
2018-05
影响因子：
11.2
通讯作者：
Albin RL
中科院分区：
文献类型：
--
作者：
Kotagal V;Spino C;Bohnen NI;Koeppe R;Albin RL
Serotoninergic neurotransmission may modulate beta-amyloid peptide (Aβ) metabolism through up-regulation of alpha-secretase. Early Parkinson disease (PD) shows variable serotoninergic denervation, which may impact Aβ deposition. We conducted three analyses to explore associations between serotoninergic neurotransmission and cerebral Aβ burden in PD. The first was a cross-sectional imaging study of PD subjects (n=23) using the serotoninergic transporter positron emission tomography (PET) ligand [11C]DASB and amyloid PET Pittsburgh compound B ([11C]PiB). The second was a baseline study of Parkinson’s Progression Markers Initiative (PPMI) subjects exploring the influence of serotoninergic medications on cerebrospinal fluid (CSF) Aβ-42 levels (n=389), controlling for age, sex, Geriatric Depression scale (GDS), disease duration, and education. Third, we fit an interval-censored proportional hazard model with longitudinal PPMI data (n=367) to test whether serotoninergic medication use associates with reduced risk of PD-cognitive-decline, defined as time to reach a Montreal Cognitive Assessment score ≤20, adjusting for baseline caudate dopamine transporter (DaT)[123I]Ioflupane single photon emission computed tomography and cerebrospinal fluid Aβ-42 levels. Serotoninergic DASB distribution volume ratio (DVR) inversely associated with PiB DVR in the cerebral cortex (Pearson’s-r=−0.478,p=0.021) but not the striatum (r=−0.264,p=0.224). In the baseline PPMI analysis, serotoninergic medication use for ≥6 months associated with a lower level of CSF Aβ-42 (t=−2.20,p=0.029). In the longitudinal PPMI model, baseline serotoninergic medication use associated with a reduced risk of cognitive decline (t=−2.03,p=0.043) after controlling for covariates. Cortical Aβ burden in PD associates inversely with serotoninergic innervation. Serotoninergic medications may alter Aβ metabolism and reduce the risk of PD cognitive decline.
登录
查看更多内容
影响因子：
6.4
作者：
Brenn, Anja;Grube, Markus;Vogelgesang, Silke
通讯作者：
Vogelgesang, Silke
影响因子：
17.7
作者：
Bartels, Claudia;Wagner, Michael;Schneider, Anja
通讯作者：
Schneider, Anja
影响因子：
11
作者：
HUGHES, AJ;DANIEL, SE;LEES, AJ
通讯作者：
LEES, AJ
DOI：
10.1073/pnas.1107411108
发表时间：
2011-09-06
影响因子：
11.1
作者：
Cirrito, John R.;Disabato, Brianne M.;Sheline, Yvette I.
通讯作者：
Sheline, Yvette I.
影响因子：
3.3
作者：
Dempsey, CM;Mackenzie, SM;Sze, JY
通讯作者：
Sze, JY